REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
5

KPV for gut inflammation results

Penn Farrell·23 days ago
After researching extensively and trying multiple approaches, I wanted to compile my findings here for others. The key takeaways are important for anyone considering this protocol.

Comments (8)

Harper HoganDEMO·2 months ago

Solid protocol. Only thing I would change is the injection site rotation. I found that alternating between more sites reduces any local reactions.

0
Aria HoganDEMO·about 2 months ago

Solid protocol. Only thing I would change is the injection site rotation. I found that alternating between more sites reduces any local reactions.

0
Taylor BishopDEMO·about 1 month ago

Solid protocol. Only thing I would change is the injection site rotation. I found that alternating between more sites reduces any local reactions.

0
Arrow DrakeDEMO·22 days ago

Solid protocol. Only thing I would change is the injection site rotation. I found that alternating between more sites reduces any local reactions.

2
Drew MarcosDEMO·21 days ago

KPV is one of those peptides that flies under the radar but has really compelling anti-inflammatory data. The alpha-MSH derivative mechanism is well understood. Were you using it orally or SubQ? Oral seems to make more sense for gut-specific issues.

0
Pax BakerDEMO·20 days ago

I used oral BPC-157 and KPV together for IBS symptoms. The combination was more effective than either alone in my experience. The BPC-157 seemed to handle the healing aspect while KPV addressed the inflammation more directly.

0
Sawyer BanksDEMO·19 days ago

Curious about the timeline of improvement. Gut healing tends to be slower than musculoskeletal improvements with peptides. My experience with KPV was that weeks 1-4 were modest improvement and then weeks 4-8 showed much more pronounced changes.

0
Reign AllenDEMO·18 days ago

The key takeaway for me is the importance of compiling findings. There is so little organized community data on KPV specifically. If you have detailed symptom tracking you should consider sharing it in a more structured format.

0

Sign in to comment.